---
layout: default
title: Dabrafenib
parent: 僅模型預測 (L5)
nav_order: 26
evidence_level: L5
indication_count: 0
---

# Dabrafenib
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Dabrafenib: Evidence Incomplete — Repurposing Evaluation Pending

## One-Sentence Summary

Dabrafenib (DrugBank: DB08912) is a small-molecule kinase inhibitor submitted for repurposing evaluation.
The current Evidence Pack (v4, 2026-04-20) contains **no TxGNN predicted indications**, **no approved indication records**, and **no safety data** — a complete evaluation report cannot be issued until the three blocking data gaps are resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in current Evidence Pack |
| Predicted New Indication | No TxGNN predictions generated |
| TxGNN Prediction Score | — |
| Evidence Level | — (no predictions to grade) |
| Taiwan Market Status | ✗ Not marketed (0 approvals) |
| Number of Authorizations | 0 |
| Recommended Decision | **Hold** |

---

## Why This Evaluation Cannot Proceed

The Evidence Pack records two blocking data gaps that prevent any repurposing analysis:

**DG001 — TFDA Package Insert (Severity: Blocking)**
Warnings and contraindications could not be retrieved from the Taiwan FDA package insert. Without this, the mandatory safety pre-screen (S1) cannot be completed, and the candidate cannot advance to mechanistic review.

**DG002 — Mechanism of Action (Severity: High)**
Despite a successful DrugBank query (result\_count: 1, 2026-03-29), MOA fields were not populated in the Evidence Pack. Mechanistic plausibility — the foundation of any repurposing rationale — cannot be assessed.

**No Predicted Indications**
The `predicted_indications` array is empty. Without TxGNN output, there is no candidate disease to evaluate, no evidence to summarise, and no repurposing hypothesis to support or refute.

Dabrafenib (DB08912) is a well-characterised targeted oncology agent. However, based solely on the data present in this Evidence Pack, this report cannot present a mechanistic rationale, clinical trial evidence, or literature summary for any new indication. Populating the gaps and re-running the pipeline is required before evaluation can continue.

---

## Cytotoxicity

Dabrafenib belongs to the BRAF kinase inhibitor class of targeted antineoplastic agents (DB08912). The following reflects drug-class knowledge; formal DrugBank toxicity data was not parsed into this Evidence Pack.

| Item | Content |
|------|---------|
| Cytotoxicity Classification | Targeted therapy (selective BRAF kinase inhibitor) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions |
| Monitoring Items | Please refer to the package insert warnings and precautions |
| Handling Protection | Handle under oncology/targeted-therapy drug handling regulations |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The Evidence Pack is missing all three components required to open a repurposing evaluation — TxGNN predicted indications, original approved indications, and a parsed safety record — making it impossible to issue any recommendation beyond Hold at this stage.

**To proceed, the following is needed:**

- **Re-run TxGNN pipeline** for Dabrafenib to generate `predicted_indications` (pipeline entry point)
- **Resolve DG002** — retrieve MOA from DrugBank API and populate `original_moa`
- **Resolve DG001** — download and parse TFDA package insert PDF to populate `key_warnings` and `contraindications`
- **Confirm original approved indications** from TFDA or international regulatory filings (FDA/EMA) and populate `original_indications`
- **Regenerate Evidence Pack** (v5) once all four items above are complete, then resubmit for evaluation
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

